The first solution could consist of changing rapamycin for dual PI3K/mTOR inhibitors like the NVP-BEZ235 which has demonstrated effectiveness in vivo (Cerniglia et al., 2012), or mTORC1/mTORC2 inhibitor is AZD2014 which radiosensitizes glioma (Kahn et al., 2014). The gene discussed is MTOR; the disease is central nervous system cancer.